Atea Pharmaceuticals, Inc. (AVIR) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -183.61M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 155.45M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-183.61M | (m) | (m) | $155.45M | (m) | (m) |
| 2026-03-31 | $-189.85M | (m) | (m) | $159.57M | (m) | (m) |
| 2025-12-31 | $-180.89M | (m) | (m) | $148.02M | (m) | (m) |
| 2025-09-30 | $-164.98M | (m) | (m) | $125.88M | (m) | (m) |
| 2025-06-30 | $-156.61M | (m) | (m) | $113.69M | (m) | (m) |
| 2025-03-31 | $-162.19M | (m) | (m) | $116.11M | (m) | (m) |
| 2024-12-31 | $-192.95M | (m) | (m) | $144.10M | (m) | (m) |
| 2024-09-30 | $-200.50M | (m) | (m) | $153.47M | (m) | (m) |
| 2024-06-30 | $-204.08M | (m) | (m) | $155.50M | (m) | (m) |
| 2024-03-31 | $-192.40M | (m) | (m) | $142.86M | (m) | (m) |
| 2023-12-31 | $-164.16M | (m) | (m) | $114.24M | (m) | (m) |
| 2023-09-30 | $-157.49M | (m) | (m) | $106.74M | (m) | (m) |
| 2023-06-30 | $-132.98M | (m) | (m) | $83.46M | (m) | (m) |
| 2023-03-31 | $-130.04M | (m) | (m) | $81.26M | (m) | (m) |
| 2022-12-31 | $-130.65M | (m) | (m) | $81.94M | (m) | (m) |
| 2022-09-30 | $30.43M | (m) | (m) | $112.21M | (m) | (m) |
| 2022-06-30 | $24.56M | (m) | (m) | $150.32M | (m) | (m) |
| 2022-03-31 | $65.55M | (m) | (m) | $170.27M | (m) | (m) |
| 2021-12-31 | $138.38M | $351.37M | (m) | $167.21M | (m) | 39.38% |
| 2021-09-30 | $37.84M | (m) | (m) | $123.24M | (m) | (m) |
| 2021-06-30 | $42.36M | (m) | (m) | $93.82M | (m) | (m) |
| 2021-03-31 | $23.67M | (m) | (m) | $61.77M | (m) | (m) |
| 2020-12-31 | $-11.03M | $48.63M | (m) | $38.02M | (m) | -22.68% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-14.61M | (m) | (m) | $10.17M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-9.48M | (m) | (m) | $6.67M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |